Table 2.
Medications in patients who achieved a CR at the end of follow-up
| TAC group | IFX group | |
|---|---|---|
| (n=17) | (n=6) | |
| Observational period (median (range)) (months) | 29 (14–118) | 32 (22–79) |
| Maintenance therapy at the end of follow-up | ||
| IFX+IM+5-ASA | 5 | 1 |
| IFX+5-ASA | 1 | 2 |
| TAC+IM+5-ASA | 3 | 0 |
| IM+5-ASA | 4 | 2 |
| IM | 1 | 0 |
| 5-ASA | 3 | 1 |
| Cumulative dosage of each drug during observational period | ||
| TAC (mean (range)) (mg) | 2852 (389–5937) | 1016 (0–2861) |
| IFX (mean (range)) (mg) | 3866 (1500–19 260) | 5843 (225–20 520) |
| IM (mean (range)) (mg) | 38 910 (7800–110 550) | 16 122 (0–42 700) |
| 5-ASA (mean (range)) (g) | 4537 (0–10 138) | 3609 (828–6994) |
Numbers of patients are shown unless specified.
5-ASA, 5-aminosalicylate; CR, clinical remission; IFX, infliximab; IM, immunomodulators; TAC, tacrolimus.